BMI-1

PTC-209 is a novel potent and selective BMI-1 inhibitor, targeting the BMI-1 self-renewal machinery with an IC50 of ~0.5 μM.

PTC-209 HBr is the hydrobromide salt of PTC-209. PTC-209 is a potent and selective BMI-1 inhibitor with IC50 of 0.5 μM in HEK293T cell line, and results in irreversible reduction of cancer-initiating cells (CICs).

PRT 4165 is an inhibitor of Bmi1/Ring1A, subunits of the polycomb repressive complex 1 (PRC1). It prevents Bmi1/Ring1A-mediated ubiquitination and drug-induced degradation of topoisomerase 2alpha.

PTC-028 is an orally bioavailable compound that decreases BMI-1 levels by posttranslational modification

PTC596 is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor.

SH498 is a novel antitumor agent that exerts its therapeutic effect through Bmi-1 inhibition. It demonstrates potent antiproliferative activity, making it a promising candidate for targeting Bmi-1–driven oncogenic pathways in cancer research and potential therapy development.

QW24 is a potent anti-tumor compound that exerts its effects by downregulating the expression of BMI-1, a key oncogenic regulator involved in cancer stem cell maintenance and tumor progression. It has demonstrated significant efficacy in preclinical models and is being explored as a promising therapeutic agent for clinical research in colorectal cancer.

1,6,7-Trihydroxyxanthone is a potent anticancer compound that inhibits tumor cell proliferation and induces apoptosis. It downregulates the expression of Bmi-1, a known oncogenic regulator, while upregulating the protein levels of tumor suppressors p14 and p16. These effects highlight its potential as a therapeutic agent for targeting oncogenic pathways in cancer research.